Keros Therapeutics Under Investigation Amid TROPOS Trial Issues and Stock Price Collapse
- Keros Therapeutics is under investigation for potential federal securities law violations related to the TROPOS trial.
- The company halted dosing in the TROPOS trial after adverse events, causing a significant stock price drop.
- Keros plans to cease all dosing in the TROPOS trial amid ongoing safety reviews and new adverse event reports.
Keros Therapeutics Faces Legal Scrutiny Amid TROPOS Trial Concerns
Keros Therapeutics, Inc. is currently under investigation by Kirby McInerney LLP for potential violations of federal securities laws and unlawful business practices. This scrutiny arises in the wake of troubling developments in the company's ongoing TROPOS trial, which evaluates the efficacy of its drug cibotercept (KER-012) for treating pulmonary arterial hypertension (PAH). The investigation highlights the challenges Keros faces as it navigates the ramifications of adverse events reported during the trial, which have significantly impacted its operations and public perception.
The TROPOS trial, a Phase 2 clinical study, has encountered serious setbacks following the observation of unexpected pericardial effusion adverse events. On December 12, 2024, Keros announced a voluntary halt to dosing in the higher treatment arms of the study, which triggered a drastic decline in its stock price, plummeting from $68.65 to $18.43—a staggering decrease of approximately 73.15%. This incident raised alarms among investors, with implications that extend beyond financial loss, potentially affecting the company’s credibility and future prospects in the competitive biopharmaceutical industry.
In a further escalation of concerns, Keros announced on January 15, 2025, that it would cease all dosing in the TROPOS trial, including the lower treatment and placebo arms. This decision was attributed to ongoing safety reviews and new adverse event observations, compounding the company's challenges and leading to an additional drop in stock price from $12.48 to $10.42. As Keros navigates these turbulent waters, the investigation by Kirby McInerney LLP underscores the importance of transparency and accountability in clinical trials, particularly as they relate to patient safety and investor trust.
In light of the recent developments, Kirby McInerney LLP is reaching out to investors who acquired Keros securities to discuss potential claims related to the alleged breaches. The law firm has a history of successful recoveries for shareholders, which may provide some reassurance to affected investors. As Keros Therapeutics continues its review of the TROPOS trial, the company's management must prioritize not only the safety of trial participants but also the restoration of investor confidence through clear communication and decisive action.